Saturday - May 10, 2025
FRAMINGHAM, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today released its 2022 sustainability report. The first annual report highlights Definitive Healthcare’s success in environmental, social, and governance practices. It also outlines social responsibility goals for 2023 to build on the established progress.
“Operating responsibly, being transparent with our various stakeholders, and being good corporate citizens within the local and global communities in which we operate are core to our values as a company,” said Robert Musslewhite, CEO of Definitive Healthcare. “Creating a sustainable business is not only the key to our success as an organization, but it’s the right thing to do for the good of our planet.”
For the inaugural report, Definitive Healthcare prioritized sustainability topics most important to its business, stakeholders, and growth, including the recruitment and management of a global, diverse, and inclusive workforce, privacy and data protection, and energy and emissions. As a result of the company’s ESG efforts in 2022, ISS ESG recognized Definitive Healthcare with “Prime” status, indicating the company was within the top 10% of issuers within the health care technology and services industry.
Some of Definitive Healthcare’s 2022 ESG achievements highlighted in the report include:
To learn more about Definitive Healthcare’s commitment to sustainability, please download the Sustainability Report.
About Definitive Healthcare
At Definitive Healthcare, our passion is to transform data, analytics, and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities, and people, so they can shape tomorrow’s healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at definitivehc.com.
Media Contacts:
Danielle Johns
djohns@definitivehc.com
Highwire PR
definitivehealthcare@highwirepr.com
Investor Relations Contact:
Brian Denyeau
ICR for Definitive Healthcare
brian.denyeau@icrinc.com
646-277-1251
Last Trade: | US$3.69 |
Daily Change: | 0.88 31.32 |
Daily Volume: | 4,227,113 |
Market Cap: | US$426.270M |
February 27, 2025 February 25, 2025 November 07, 2024 October 10, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load